Literature DB >> 34094767

Coronavirus Disease 2019 Infection as a Risk Factor for Infective Endocarditis.

Dilesha Kumanayaka1,2, Monica Mutyala3,2, Dhinesh V Reddy1,2, Jihad Slim3,2.   

Abstract

Infective endocarditis (IE) is associated with relatively high morbidity and mortality and several risk factors have been identified in the past. Several predisposing factors for IE have been recognized in the literature, depending on the type of bacteria. Coronavirus disease 2019 (COVID-19) infection causes coagulopathy-associated complications and damage to many organ systems due to the inflammatory response induced by this viral infection. COVID-19 emerged only about a year ago and there are many unknown post-COVID-19 complications at this time. Here, we present the case of Streptococcus mitis IE in a patient with no prior predisposing factors other than diagnosis with COVID-19 a month ago.
Copyright © 2021, Kumanayaka et al.

Entities:  

Keywords:  covid-19; covid-19 coagulopathy side effects; covid-19 endocarditis; cytokine storms; hypercoagulopathy; infective endocarditis; sars-cov-2 infection

Year:  2021        PMID: 34094767      PMCID: PMC8171987          DOI: 10.7759/cureus.14813

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


Introduction

Infection of the endocardial surface of the native valve, prosthetic heart valve, or an implanted cardiac device is known as infective endocarditis (IE). IE is a disease with relatively high morbidity and mortality [1-6]. Risk factors for IE usually involve two elements, the first is a transient bacteremia that could originate from dental infections, surgical procedures in the oral cavity, indwelling intravenous catheters, intravenous drug abuse, or infections of the skin, lungs, intestine, and urinary tract; the second is an abnormal valve either secondary to a congenital heart disease, degenerative disease, or prior surgical intervention. Commonly reported organisms causing IE include Staphylococci, Streptococci, Enterococci, and HACEK (Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, and Kingella). Staphylococcus aureus has surpassed viridans streptococci as the most common cause of IE in recent years [3-6]. Mitral and aortic valves are the most commonly infected valves [3-6]. We present a unique case of IE caused by Streptococcus mitis on a structurally normal native mitral valve, where the only risk factor the patient had was a recent coronavirus disease 2019 (COVID-19) infection.

Case presentation

A 38-year-old male with no known past medical history (PMH) presented with fevers/chills, night sweats, and periumbilical, non-radiating, and dull pain for about a week associated with anorexia and fatigue. He reported 20-pound weight loss in the prior month and had tested positive for COVID-19 a month earlier. According to the patient, he was hospitalized for four to five days with hypoxic episodes, requiring supplemental oxygen and received dexamethasone as well as anticoagulation. He did not have any risk factors for IE such as intravenous drug use, congenital heart disease, prosthetic heart valves, prior IE, or any recent dental procedure. On physical examination, he did not have any findings of heart murmurs and immunological/vascular skin findings. A complete septic workup was performed and demonstrated elevated erythrocyte sedimentation rate at 105 mm/hour (normal: 0-30 mm/hour), C-reactive protein at 15.6 mg/dL (normal: 0.0-0.8 mg/dL), white blood cells 11.4 × 103/uL (normal 4.4-11 × 103/uL), hemoglobin 12.2 × 103/uL (normal: 13.5-17.5 × 103/uL), and platelets 317 × 103/uL (normal: 150-450 × 103/uL). Urinalysis was normal and one set of blood cultures grew half bottles of Streptococcus mitis/oralis,with the next set of blood cultures a day apart showing no growth. A computed tomography scan of the abdomen was also done as the patient was complaining of pain and showed a 11 mm hypodensity in the spleen, suggesting an infarction. Transthoracic echocardiogram was performed, which could not exclude mitral valve endocarditis, but transesophageal echocardiogram (TEE) showed vegetation on the anterior mitral valve leaflet (Figure 1). He tested positive for COVID-19 IgG and negative for IgM. Antigen and polymerase chain reaction tests were also negative. He was discharged on ceftriaxone 2 g intravenously for six weeks via a PICC line and was followed up in the outpatient setting. His weekly labs were unremarkable and his repeat TEE did not show any vegetations.
Figure 1

TEE showing a vegetation on the anterior mitral valve leaflet.

TEE: transesophageal echocardiogram

TEE showing a vegetation on the anterior mitral valve leaflet.

TEE: transesophageal echocardiogram

Discussion

Cardiovascular disease is the most common comorbidity associated with COVID-19 infection, as per the published literature to date. It is important to understand that severe COVID-19 disease can lead to serious long-term complications. Our patient had no significant PMH and no physical examination findings to suspect IE, but suspicion was high given the positive Duke’s score of one major criteria (TEE showing vegetation) and three minor criteria (pyrexia, vascular phenomena of splenic infarct, and one blood culture positive for Streptococcus mitis) [4-6]. In this case, as the patient did not have any risk factors for IE and had a history of hospitalization for severe COVID-19 disease, it can be suggested that the damage to the mitral valve structure by the cytokine storm with the systemic inflammation [1,2,7] and the hypercoagulable state induced by prior COVID-19 infection contributed as risk factors. The process of vegetation is initiated through a transient bacteremia, which causes organisms to adhere to the previously damaged endothelium [1,7]. The upregulated coagulation state by recent COVID-19 infection further helps microorganisms to encase in a platelet/fibrin matrix on the heart valve structure [1,7]. To the best of our knowledge, there have been no prior cases reported in the literature that proposes history of COVID-19 infection as a risk factor for future IE incidents.

Conclusions

COVID-19 has been known to cause hyperinflammatory response along with hypercoagulable state leading to various complications. This case highlights the importance of considering prior COVID-19 infection as a possible risk factor for IE, especially in the absence of other predisposing factors, due to the organ damage that can result from inflammatory response and hypercoagulable state secondary to COVID-19 infection. This case significantly benefits the fields of cardiology, infectious diseases, as well as other fields of internal medicine in the face of unprecedented challenges brought by a global pandemic. We hope that this novel case influences the approach to diagnosing IE in patients who have a history of COVID-19 infection. More studies that explore advantages of receiving treatment for COVID-19 infection in regards to post-disease complications would be beneficial.
  7 in total

1.  Pathology and pathogenesis of infective endocarditis in native heart valves.

Authors:  Gaetano Thiene; Cristina Basso
Journal:  Cardiovasc Pathol       Date:  2006 Sep-Oct       Impact factor: 2.185

2.  Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011.

Authors:  Sadip Pant; Nileshkumar J Patel; Abhishek Deshmukh; Harsh Golwala; Nilay Patel; Apurva Badheka; Glenn A Hirsch; Jawahar L Mehta
Journal:  J Am Coll Cardiol       Date:  2015-05-19       Impact factor: 24.094

3.  Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study.

Authors:  David R Murdoch; G Ralph Corey; Bruno Hoen; José M Miró; Vance G Fowler; Arnold S Bayer; Adolf W Karchmer; Lars Olaison; Paul A Pappas; Philippe Moreillon; Stephen T Chambers; Vivian H Chu; Vicenç Falcó; David J Holland; Philip Jones; John L Klein; Nigel J Raymond; Kerry M Read; Marie Francoise Tripodi; Riccardo Utili; Andrew Wang; Christopher W Woods; Christopher H Cabell
Journal:  Arch Intern Med       Date:  2009-03-09

4.  2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).

Authors:  Gilbert Habib; Patrizio Lancellotti; Manuel J Antunes; Maria Grazia Bongiorni; Jean-Paul Casalta; Francesco Del Zotti; Raluca Dulgheru; Gebrine El Khoury; Paola Anna Erba; Bernard Iung; Jose M Miro; Barbara J Mulder; Edyta Plonska-Gosciniak; Susanna Price; Jolien Roos-Hesselink; Ulrika Snygg-Martin; Franck Thuny; Pilar Tornos Mas; Isidre Vilacosta; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

Review 5.  COVID-19 and Cardiovascular Disease.

Authors:  Kevin J Clerkin; Justin A Fried; Jayant Raikhelkar; Gabriel Sayer; Jan M Griffin; Amirali Masoumi; Sneha S Jain; Daniel Burkhoff; Deepa Kumaraiah; LeRoy Rabbani; Allan Schwartz; Nir Uriel
Journal:  Circulation       Date:  2020-03-21       Impact factor: 29.690

Review 6.  COVID-19 concomitant with infective endocarditis: A case report and review of management.

Authors:  Muzakkir Amir; Irawaty Djaharuddin; Albert Sudharsono; Sri Ramadany
Journal:  Int J Infect Dis       Date:  2020-06-20       Impact factor: 3.623

7.  Cardiac complications in patients hospitalised with COVID-19.

Authors:  Marijke Linschoten; Sanne Peters; Maarten van Smeden; Lucia S Jewbali; Jeroen Schaap; Hans-Marc Siebelink; Peter C Smits; Robert G Tieleman; Pim van der Harst; Wiek H van Gilst; Folkert W Asselbergs
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2020-11-21
  7 in total
  4 in total

1.  Trends of Myocarditis and Endocarditis Cases before, during, and after the First Complete COVID-19-Related Lockdown in 2020 in France.

Authors:  Thibaut Pommier; Eric Benzenine; Chloé Bernard; Anne-Sophie Mariet; Yannick Béjot; Maurice Giroud; Marie-Catherine Morgant; Eric Steinmetz; Charles Guenancia; Olivier Bouchot; Catherine Quantin
Journal:  Biomedicines       Date:  2022-05-25

2.  A clinical profile of infective endocarditis in patients with recent COVID-19: A systematic review.

Authors:  Juan A Quintero-Martinez; Joya-Rita Hindy; Maryam Mahmood; Danielle J Gerberi; Daniel C DeSimone; Larry M Baddour
Journal:  Am J Med Sci       Date:  2022-02-27       Impact factor: 3.462

Review 3.  Native aortic valve Staphylococcus warneri endocarditis after COVID-19 infection: a case report and a review of literature.

Authors:  Ram Gelman; Assaf Potruch; Yonatan Oster; Yuval Ishay; Chamutal Gur; Ronen Beeri; Jacob Strahilevitz
Journal:  APMIS       Date:  2022-03-11       Impact factor: 3.428

4.  A Challenge of COVID-19: Associated Infective Endocarditis with Streptococcus gordonii in a Young Immunocompetent Patient.

Authors:  Manuela Arbune; Alina-Viorica Iancu; Gabriela Lupasteanu; Mihaela-Camelia Vasile; Victorita Stefanescu
Journal:  Medicina (Kaunas)       Date:  2021-11-26       Impact factor: 2.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.